ICON Public (NASDAQ:ICLR – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 13.900-14.100 for the period, compared to the consensus EPS estimate of 15.060. The company issued revenue guidance of $8.3 billion-$8.3 billion, compared to the consensus revenue estimate of $8.5 billion. ICON Public also updated its FY24 guidance to $13.90-14.10 EPS.
ICON Public Trading Down 21.0 %
Shares of ICLR traded down $59.03 during trading hours on Thursday, hitting $221.73. 6,190,963 shares of the stock traded hands, compared to its average volume of 611,493. The business has a fifty day moving average of $301.78 and a 200-day moving average of $311.59. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $18.29 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22. ICON Public has a 1-year low of $220.51 and a 1-year high of $347.72.
ICON Public (NASDAQ:ICLR – Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.10 EPS. Analysts expect that ICON Public will post 14.54 EPS for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on ICON Public
ICON Public Company Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading
- Five stocks we like better than ICON Public
- How to Buy Cheap Stocks Step by Step
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- 3 Fintech Stocks With Good 2021 Prospects
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 5 discounted opportunities for dividend growth investors
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.